Sol-Gel Technologies Ltd. Initial Statement of Beneficial Ownership
Sol-Gel Technologies Ltd. executive Ofra Levy-Hacham, VP Clinical, Regulatory & Quality, filed an initial Form 3 reporting her beneficial ownership of several stock option grants over the company’s ordinary shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Sol-Gel Technologies Ltd. executive Ofra Levy-Hacham, VP Clinical, Regulatory & Quality, filed an initial Form 3 reporting her beneficial ownership of several stock option grants over the company’s ordinary shares. These options are held directly, with exercise prices ranging from $8.96 to $100.00 per share and expiration dates between August 2026 and February 2035.
According to the filing, some of the options are already fully vested, while others began vesting 25% on specific dates in 2023, 2024, and 2026 and will continue to vest in equal quarterly installments over the following three years, subject to her continued service with the company.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Stock Option (right to buy) | -- | -- | -- |
| Holding | Stock Option (right to buy) | -- | -- | -- |
| Holding | Stock Option (right to buy) | -- | -- | -- |
| Holding | Stock Option (right to buy) | -- | -- | -- |
| Holding | Stock Option (right to buy) | -- | -- | -- |
Footnotes (6)
- F1. Ordinary shares, NIS 1.00 par value per share.
- F2. The option is fully vested.
- F3. The option is fully vested.
- F4. The option vested as to 25% of the Ordinary Shares on March 29, 2023 and vests as to the remainder of the Ordinary Shares in equal quarterly installments over the following three years, subject to the Reporting Person's continued service through such dates.
- F5. The option vested as to 25% of the Ordinary Shares on March 9, 2024 and vests as to the remainder of the Ordinary Shares in equal quarterly installments over the following three years, subject to the Reporting Person's continued service through such dates.
- F6. The option vested as to 25% of the Ordinary Shares on February 18, 2026 and vests as to the remainder of the Ordinary Shares in equal quarterly installments over the following three years, subject to the Reporting Person's continued service through such dates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
